$IBRX If you end up in an ICU with sepsis, your doctor has antibiotics and hope. That's it. 200,000 Americans die every year. No immunotherapy exists. The science to change this has existed since 2010. Sixteen years, sitting in a journal. Nobody built the drug. Until now. The

$IBRX The NCI suppressed the scientist who discovered NK cells. Now the FDA is fighting @DrPatrick who built a drug to activate them. In 1969, a scientist named Joseph Sinkovics drew his own blood, mixed it with a patient's cancer cells, and watched his lymphocytes kill them. He

Capital in place.Approvals in 34 countries. Indication expansion globally in motion. Pipeline of combination trials cooking. Immunotherapy 2.0. Never give up.

$IBRX They shorted the warning letter. Two weeks later: $100M non-dilutive financing. The founder converting his own debt into equity. 34 countries. $375M committed. Every domino that falls builds the empire and tightens the trap. What Just Happened $100M financing. $75M

Strengthening the balance sheet. Recharging for global expansion. Stay tuned.

Excited to be invited by a health minister in Europe to visit to establish immunotherapy2.0 ….global expansion of the power of NK and T cells. The need to address the rising number of cancer in younger patients is being realized around the world.

$IBRX Update: The IDMC result is in. Yesterday I posted three possible outcomes for the BCG-naive trial. Here's what happened. The Result The Independent Data Monitoring Committee confirmed that N=366 is sufficient to detect clinically meaningful differences between ANKTIVA +

$IBRX While the market panics over a warning letter about a podcast, @DrPatrick just quietly dropped the most important clinical update of the year. 3,503 views. This deserves more. What Happened The BCG-naive randomized trial (QUILT-2.005) hit its 50% evaluable milestone -

$IBRX While the market digests a warning letter about a podcast (corrective actions already underway - see my prior post), PSS just showed where the 3-year plan actually stands. What's Been Delivered - Bladder cancer CIS: FDA approved (April 2024) - Papillary expansion: NCCN

$IBRX For those asking about the podcast still being on YouTube - the FDA warning letter cited the podcast because ImmunityBio hosted it on their corporate website without required risk disclosures. That's what made it a promotional violation. The same content living on

Update:

$IBRX The stock dropped 21%. The website is already corrected. The podcast is down. I checked every source cited across all three FDA communications myself. Already Corrected: The Website (Flagged Sept 2025 + Jan 2026) The FDA's two prior letters targeted the

$IBRX The FDA issued a warning letter to ImmunityBio on March 13. I cover catalysts and risks. Here's what this actually means. What It Is The letter comes from OPDP - the Office of Prescription Drug Promotion. This is the division that polices marketing. Not the division that

$IBRX The Wall Street Journal just broke an exclusive: the Trump administration is launching a $200 million cancer vaccine initiative through the Department of Health & Human Services and the National Cancer Institute. Then @DrPatrick tweeted something that deserves a closer look

Global expansion-first approval in Asia!! Anktiva now approved in Macau, China today. Paradigm change of treating the immune system unstoppable.

$IBRX spiked above $9 on the NCCN Category 2A listing, then closed red. If you're worried, read this. If you've seen this before, you already know what comes next. The Pattern That Repeats Across Every Heavily Shorted Stock There is a playbook that shorts run on catalyst days.

$IBRX shorts right now

Next episode:

Previous episode:

Two days ago I published S15: The Trap. Episode 7 listed seven catalysts loaded against $IBRX short sellers. The first one just fired. The FDA Said No. The NCCN Just Said Yes. NCCN updated Bladder Cancer Guidelines to Version 1.2026. ANKTIVA + BCG is now listed as "Other